I-22 Silvia Illamola Population pharmacokinetics of amikacin in newborns Wednesday 10:15-11:45 |
I-50 Chiara Piana Non-adherence to antiretroviral combination therapy in HIV-infected children Wednesday 10:15-11:45 |
I-64 Roel Straetemans Pharmacokinetic/Pharmacodynamic Simulations Of The vWF Targeting Nanobody® ALX-0081 In Pediatric Patients With TTP Wednesday 10:15-11:45 |
II-04 Nikolaos Tsamandouras Mapping in vitro and in vivo derived CYP3A ontogeny function: A critical comparison between various ontogeny models Wednesday 15:10-16:40 |
II-37 Mirjam Trame Evaluating the Influence of Different Covariates on Enoxaparin Pharmacokinetics in Neonates, Infants and Children Wednesday 15:10-16:40 |
II-41 Marta Valle Population pharmacokinetics of rupatadine in children 2-11 years of age with allergic rhinitis Wednesday 15:10-16:40 |
II-42 Sven van Dijkman Characterisation of response and disease progression in paediatric epilepsy Wednesday 15:10-16:40 |
II-44 Charlotte van Kesteren Predictive performance of a busulfan pharmacokinetic-model in children and young adults from five international transplant centers: a study of varying doses, underlying diseases, ethnicities, body weights, ages and body mass indices Wednesday 15:10-16:40 |
II-55 Chenguang Wang Scaling morphine across the human life-span using a bodyweight-dependent allometric exponent model Wednesday 15:10-16:40 |
II-65 Wei Zhao Population pharmacokinetics and dosing optimization of vancomycin continuous infusion in neonates Wednesday 15:10-16:40 |
III-01 Khaled Abduljalil Predicting the Developmental PK/PD of Cyclosporine (CsA) in Paediatrics Thursday 10:05-11:35 |
III-13 Francesco Bellanti Deferiprone sampling optimisation in a pharmacokinetic bridging study including children with β-thalassaemia Thursday 10:05-11:35 |
IV-06 Anne-Kristina Mercier A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A Thursday 15:00-16:30 |
IV-30 Lutz Harnisch Determining the Pharmacokinetic (PK) Profile of Sildenafil in One Month to One Year Old Pediatric Pulmonary Arterial Hypertension (PAH) Patients Using Interpolation of Two Population Pharmacokinetic Models of Sildenafil in PPHN population (3 to 10 Days Old) and in Pediatric PAH population (1 to 17 Years Old) Thursday 15:00-16:30 |
IV-34 Sarapee Hirankarn Pharmacokinetics Of High-Dose Methotrexate In Children With Cancer: A Mechanism Based Evalution Of Clearance Prediction Thursday 15:00-16:30 |
IV-55 Nastya Kassir A Modelling and Simulations Framework to Optimize Paediatric Studies and Facilitate Decision-Making Thursday 15:00-16:30 |
IV-60 Elke Krekels Top-Down Modeling Meets Bottom-Up Modeling: The Physiological and Physicochemical Basis for the Ontogeny of UGT2B7-Mediated Drug Glucuronidation. Thursday 15:00-16:30 |
IV-64 Brigitte Lacroix A single population pharmacokinetic model for oral levetiracetam in various populations – dose investigation for Japanese children Thursday 15:00-16:30 |
IV-68 Christian Laveille Use of an exposure-response model for lacosamide in adults with partial onset seizures to analyze preliminary data from a pediatric trial Thursday 15:00-16:30 |